{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:41:24Z","timestamp":1793155284158,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Upadacitinib, one of the Janus kinase (JAK) inhibitors, has gained global approval for treating various inflammatory and autoimmune diseases. However, despite the FDA\u2019s black box warning on all JAK inhibitors, further research is necessary to verify the potential risks associated specifically with upadacitinib. Therefore, this study conducted a comprehensive systematic review and meta-analysis to assess the safety profile of upadacitinib and explore potential dose-related differences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Relevant English publications were identified through a comprehensive search of eligible databases conducted in March 2024 and subsequently updated in May 2025. The inclusion criteria focused on randomized controlled trials that included safety data on upadacitinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 9,547 patients were involved in this meta-analysis. Upadacitinib treatment was associated with an increased risk of hepatic disorder, neutropenia, acne, herpes zoster, and increased creatine phosphokinase levels. Notably, the risks of hepatic disorder, neutropenia, and acne also exhibited a dose-dependent relationship. However, there was no significant association between upadacitinib treatment and an elevated risk of renal dysfunction, non-melanoma skin cancer (NMSC), major adverse cardiovascular event (MACE), or venous thromboembolic event (VTE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study reveals that upadacitinib generally has a favorable safety profile, with increased risks of hepatic disorder, neutropenia, acne, especially at higher doses. There was no significant association with renal dysfunction, NMSC, MACE, or VTE. These findings may serve as an evidence base for potential future modifications or removal of the FDA\u2019s black box warning for upadacitinib.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1598972","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:21:25Z","timestamp":1750656085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Cong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1097\/RHU.0000000000001749","article-title":"The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis","volume":"2","author":"Alves","year":"2022","journal-title":"J. Clin. Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"20","author":"Blockmans","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"10139","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"10341","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10349","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety","volume":"4","author":"Elmariah","year":"2022","journal-title":"Am. J. Clin. Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"11","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"10139","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure up 1 and Measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"10290","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"3","author":"Guttman-Yassky","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies","volume":"1","author":"Guttman-Yassky","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study","volume":"11","author":"Kameda","year":"2020","journal-title":"Rheumatol. Oxf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/1346-8138.16307","article-title":"Case of molluscum contagiosum of an aged female in association with the use of upadacitinib","volume":"5","author":"Kawano","year":"2022","journal-title":"J. Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ard.2025.01.024","article-title":"Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statement","volume":"5","author":"Konzett","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"21","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"13","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"3","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","article-title":"Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials","volume":"4","author":"Mendes-Bastos","year":"2022","journal-title":"J. Am. Acad. Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"10","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/jcph.1375","article-title":"Characterization of the effect of renal impairment on upadacitinib pharmacokinetics","volume":"6","author":"Mohamed","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14740338.2019.1577817","article-title":"Update upon the infection risk in patients receiving TNF alpha inhibitors","volume":"3","author":"Murdaca","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamadermatol.2024.3696","article-title":"Upadacitinib in adolescents with moderate to severe atopic dermatitis: analysis of 3 phase 3 randomized clinical trials through 76 weeks","volume":"160","author":"Paller","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10290","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"8","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e8227","DOI":"10.1002\/ccr3.8227","article-title":"Symptomatic creatine phosphokinase elevation in a Crohn's disease patient caused by upadacitinib","volume":"1","author":"Schuitema","year":"2024","journal-title":"Clin. Case Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13317-021-00153-5","article-title":"Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"1","author":"Solipuram","year":"2021","journal-title":"Auto. Immun. Highlights"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"2","author":"Szekanecz","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(19)32681-9","article-title":"JAK inhibitors: promising for a wider spectrum of autoimmune diseases?","volume":"10214","author":"Tektonidou","year":"2019","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/jdv.18027","article-title":"Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study","volume":"6","author":"Thyssen","year":"2022","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"11","author":"van der Heijde","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e002280","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","volume":"8","author":"van der Heijde","year":"","journal-title":"RMD Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"10214","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S2468-1253(23)00208-X","article-title":"Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study","volume":"11","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"2","author":"Winthrop","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","article-title":"A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/1756-185X.14235","article-title":"Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy","volume":"12","author":"Zeng","year":"2021","journal-title":"Int. J. Rheum. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1598972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:21:26Z","timestamp":1750656086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1598972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":38,"alternative-id":["10.3389\/fphar.2025.1598972"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1598972","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"article-number":"1598972"}}